chrisvoncsefalvay/vaers-outcomes huggingface dataset:
muscular pain; tiredness; his vaccination site is also very sore; Nervous; achy body; chills; Feeling sick; feeling rough; Shaky; Achy lower back like in the liver or kidney area; headache; not being able to sleep well; anxious feeling; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 56 year-old male patient received bnt162b2 (BNT162B2), administration date 08Apr2021 (Lot number: EW0158) at the age of 56 as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 (Manufacturer Unknown, Dose 1.), for COVID-19 immunisation. The following information was reported: PAIN (non-serious) with onset 08Apr2021, outcome "unknown", described as "achy body"; MYALGIA (non-serious), outcome "unknown", described as "muscular pain"; HEADACHE (non-serious) with onset 08Apr2021, outcome "unknown", described as "headache"; INSOMNIA (non-serious) with onset 08Apr2021, outcome "unknown", described as "not being able to sleep well"; ANXIETY (non-serious) with onset 08Apr2021, outcome "unknown", described as "anxious feeling"; FATIGUE (non-serious), outcome "unknown", described as "tiredness"; CHILLS (non-serious) with onset 08Apr2021, outcome "unknown", described as "chills"; MALAISE (non-serious) with onset 08Apr2021, outcome "unknown", described as "Feeling sick"; DRY SKIN (non-serious) with onset 08Apr2021, outcome "unknown", described as "feeling rough"; NERVOUSNESS (non-serious) with onset 08Apr2021, outcome "unknown", described as "Shaky"; BACK PAIN (non-serious) with onset 08Apr2021, outcome "unknown", described as "Achy lower back like in the liver or kidney area"; VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "his vaccination site is also very sore"; NERVOUSNESS (non-serious) with onset 08Apr2021, outcome "unknown", described as "Nervous".  Additional Information: The information provided as per medical information requested and there was no product complaint, no other conditions and investigations to report. NDC number and expiry date for Lot number was not provided. Patient administered 2 Alka-Seltzer tablets with about 8 ounces of water to treat adverse events headache, chills, feeling sick, achy all over, anxious which helped the patient. For events insominia and back pain patient administered Ibuprofen and Gabapentin. Patient was injured previously and took therapeutic measures for pain in his back.  No follow-up attempts are possible. No further information is expected.
Patient presented to the ED for evaluation of chest pain. About 24-48 hours after receiving vaccination he started having left sided chest pain that worsened over the next 3-4 days. The pain intensified and he also reports having low grade fevers.
This spontaneous report as received from a unspecified employee via company representative refers to a 12 year old male patient. The patient had received the first dose of VARIVAX (Merck) as a younger child (dates unspecified). On 23-AUG-2013, the patient was vaccinated with a second dose of VARIVAX (Merck) (lot number, expiry date, route and dose were not reported). Approximately on 06-SEP-2013 (reported as 2 weeks after vaccination), the patient broke out in a shingles rash on his neck. Patient sought medical attention and had been to an unspecified health care professional (HCP). The HCP diagnosed the patient with Shingles on 07-SEP-2013. The rash was being covered by a Band-Aid and no other treatment was given. The outcome of broke out in a shingles rash on his neck was reported as not recovered/not resolved. Additional information has been requested.
Within 12 hours of receiving my first dose between 06:00-9:00PM I had mild fever, chills, tired and felt like I had the flu. Those symptoms where gone exactly 12 hours later. No medical care was needed.
flu like symptoms; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose 1,single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: INFLUENZA LIKE ILLNESS (non-serious), outcome "unknown", described as "flu like symptoms".  Additional information: It was reported that the patient was supposed to receive her second dose now (at the time of report).  The lot number for bnt162b2 was not provided and will be requested during follow up.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PALPITATIONS (hospitalization), outcome "unknown", described as "heart palpitations"; HEART RATE INCREASED (hospitalization), outcome "unknown", described as "patient's heart was racing very fast". Clinical course: caller was calling because caller's friend got the first Pfizer COVID-19 vaccine and had a reaction to the shot. Caller's friend is a nurse. Caller's friend, the patient, was in the hospital because it affected the patient's heart. Caller mentions heart palpitations, but doesn't know what it was, maybe heart palpitations, patient's heart was racing very fast. Patient was scared to get the second shot, now they threatened the patient's job and the patient hasn't worked in 5 weeks. Patient got an exemption from the doctor that the patient was exempt from getting the second shot. There were other coworkers that have not gotten the shot at all. Patient was admitted to the hospital where the patient works so they have the patient's medical records. The patient underwent the following laboratory tests and procedures: Heart rate: Increased. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
severe pain in her arm that she can't even to put her jacket after 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (severe pain in her arm that she can't even to put her jacket after 2nd dose) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004C21A and 036B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included Birth Control and BUPROPION HYDROCHLORIDE (WELLBUTRIN) for an unknown indication.   On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-May-2021, the patient experienced MYALGIA (severe pain in her arm that she can't even to put her jacket after 2nd dose). At the time of the report, MYALGIA (severe pain in her arm that she can't even to put her jacket after 2nd dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient Tylenol medication and applied cold compress, to relieve the symptoms. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine was not applicable.   This case was linked to MOD-2021-118642 (Patient Link).
Staff reported that he wasn't being himself. He was leaning more towards the right. Had symptoms similar to Bell's Palsy, some right sided facial droop, right eyelid drooping. On CT right maxillary sinusitis, ventriculomegaly.
clustered dots/ Red Dots; Itchy dots at the injection site; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Sore arm), VACCINATION SITE ERYTHEMA (clustered dots/ Red Dots) and VACCINATION SITE PRURITUS (Itchy dots at the injection site) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-May-2021, the patient experienced MYALGIA (Sore arm). On 23-May-2021, the patient experienced VACCINATION SITE ERYTHEMA (clustered dots/ Red Dots) and VACCINATION SITE PRURITUS (Itchy dots at the injection site). On 17-May-2021, MYALGIA (Sore arm) outcome was unknown. At the time of the report, VACCINATION SITE ERYTHEMA (clustered dots/ Red Dots) and VACCINATION SITE PRURITUS (Itchy dots at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication information not provided.  Treatment information not provided.
patient was supposed to receive the new updated covid19 booster shot (bivalent) and ended up receiving the monovalent
Expired vaccine administered; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066F21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medications were reported. HCP reported vial with lot(066F21A) which was expired on 3-Apr-2022.was administered to total of 24 patients including 15 males and 9 females. HCP reports administrations were mostly for booster shots. No side effects was reported No treatment information was provided.
This spontaneous report as received from a other health professional refers to a 75 year old male patient. The patient's medical history included shingles on an unspecified date approximately on July 2012 (reported as last year). On 19-JUL-2013 the patient was vaccinated with a dose of ZOSTAVAX (lot # J001005, expiration date and route not reported) in the left arm. On an unknown date in July 2013, the patient experienced rash and lump. The event resolved on an unknown date in July 2013. Causality was not reported. Additional information has been requested.
I experienced a breakthrough case of COVID-19 with aches, sore throat, bed rest for a few days. 5 days later I tested negative.
Information has been received from a 27 year old female, through the pregnancy registry for varicella virus vaccine live, with no allergies or other pertinent medical history who on 21-Mar-2003 was vaccinated with a dose of varicella virus vaccine live. There was no concomitant therapy. The patient reported that on 02-Apr-2003, she developed chickenpox. The patient did not seek medical attention and simply took acetaminophen (Tylenol). On 08-Apr-2003, the patient recovered from the chickenpox. On approximately 12-Apr-2003, the patient became pregnant. Additional information has been requested.
Patient reports weakness, tiredness and heaviness in the eyes. Doctor is notified, who orders hydration by mouth until he is evaluated again.
Headache-36hrs - Ibuprofen. Nausea - 12hrs. Burning flashes - 1 HR. Swollen throat - 36hrs.
Patient received the first Moderna COVID-19 Vaccine dose on 4/21/21 and the second dose of Moderna COVID-19 Vaccine on 5/24/21. For unknown reason (not documented in chart) patient also received a third booster dose on 11/03/21 which is 163 days after the second dose. The recommended waiting period between booster and second dose is 168 days (7 days/week x 4 weeks/month x 6 months). There were no adverse events associated with administration of the vaccine. Per CDC guidance, doses inadvertently administered earlier than the grace period should not be repeated.
expired vials were used to provide 38 doses; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (expired vials were used to provide 38 doses) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049E21A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (expired vials were used to provide 38 doses). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (expired vials were used to provide 38 doses) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  No vial went any temperature excursions.  On 12-Nov-2021, all vaccines were administered within 2 hours.  Some of patient received booster dose on 1-Nov-2021, 05-Nov-2021, 11-Nov-2021 and 12-Nov-2021. Till 19-Nov-2021, there were no adverse reactions to the vaccine.  As of 19 Nov 2021, there were no adverse reactions to the vaccine reported by the list below. We spoke with some that received the vaccine during these dates and some identified common side effects after the vaccine (ex: sore arm, etc.) and only lasted for a few hours but no more than 24 hours for 1st dose, 2nd dose and Booster.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 18-Nov-2021: The additional information included suspect administration date. On 19-Nov-2021: Follow-up information included about patients details On 19-Nov-2021: Significant FU appended (Second reporter Information was updated)
The 12-year-old male patient was inadvertently administered a pediatric dose (0.2 mL) IM to the right arm by the vaccinator. The patient was 11 years old when they received their first pediatric dose on 11/6/2021. The 12-year-old patient and guardian were informed of the dosing error and requested to receive the full adult dose (30 ug). Per the Pediatrician, an additional 0.4 mL of the pediatric Pfizer vaccine was recommended to the 12-year-old patient and guardian to provide the full adult dose. The 12-year-old patient was administered their 2nd pediatric Pfizer dose (0.4 mL). The 12-year-old patient and guardian reported no signs or symptoms of an adverse reaction during the 15-30 min observation period.
Resident was vaccinated on 7/14/22 approximately 1430. Resident spiked temp of 102 , generalized weakness, lethargy, and increased confusion. 24 hours later. Resident went into clinic and was told per PA that symptoms were result of adverse reaction to COVID-19 vaccine. Resident continued to become weaker and ended up falling and was sent to ER and admitted to Hospital in 7/17/22. Resident was then started on comfort cares and passed away on 7/20/22. Unknown if cause of death was directly related to vaccine or if death was due to underlying conditions.
Extreme fatigue at hour 8. After hour 10, all over body muscle aches, and head congestion.
This case was reported by a pharmacist and described the occurrence of vaccination adverse reaction in a female subject of unspecified age who was vaccinated with HAVRIX (GlaxoSmithKline). Concurrent medical conditions included allergy to aluminum. On an unspecified date the subject received unspecified dose of HAVRIX (details unknown). At an unspecified time after vaccination with HAVRIX, the subject experienced vaccination adverse reaction. The type of reaction was unknown as the pharmacist had limited information. At the time of reporting the outcome of the event was unspecified. Follow up received from reporting pharmacist on 17 July 2009: This case described the occurrence of vaccination adverse reaction in a 26-year-old female subject who was vaccinated with HAVRIX (GlaxoSmithKline), HPV (Unknown manufacturer). Concurrent medications included allergy to aluminum, allergy to yeast and anxiety. Details regarding tobacco or alcohol use were not known. Previous and/or concurrent vaccination included Hep B (manufacturer unspecified; unknown) given on 25 June 1998 and 17 August 1998; yellow fever vaccine (manufacturer unspecified; subcutaneous) given on 05 May 2009. On an unspecified date the subject received 1st dose of HPV (detail unknown). At an unspecified time after vaccination with HPV, the subject experienced an allergic reaction (details not specified). The subject stated that she was "now hypersensitivity to yeast and aluminum". On 8 May 2009 the subject received 1st dose of HAVRIX (intramuscular, route unknown). During a wait of 30 minutes after vaccination with HAVRIX, the subject experienced dizziness, lip burning and itchy throat. She was taken to the urgent care facility and was treated with antihistamines and observed. The reporting pharmacist stated that "she was okay when she left". The date of onset for vaccination adverse reaction was reported as 08 May 2006 with resolution date of 12 May 2006, but this was commented as "not verified". The pharmacist considered the events which occurred on 08 May 2009 were clinically significant (or requiring intervention). At the time of reporting the events were resolved. The vaccination course with HAVRIX was discontinued. The pharmacist considered the events were related to vaccination with HAVRIX and HPV. The pharmacist also stated that the subject was very anxious at travel visit, and was also "anxious about getting shots and symptoms related to shot". The pharmacist also considered the events could have been associated with the prior allergic reaction to HPV, but noted that the HAVRIX insert does not identify aluminum as an ingredient.
Dizziness -almost passing out 3 times 2 periods in May Nausea/diarrhea  Headaches/pressure Fatigue Shooting chest pains  Left arm/fingers cold to touch/tingly Both legs feel heavy/tingly; just want to do nothing but sit down Will be calling Clinic Tues after holiday; if symptoms worsen prior to then I will be calling local urgent care
My daughter's symptoms were allergy throughout the body and burning pain in the left arm where the vaccine was administered, she also had 3 blisters on the same side where the vaccine was administered in the elbow, in the thigh and in the knee the treatment that The doctor gave him medicine.
Still does not feel right, like when she swallows/Touch or swallow feels different like she has a lump in her throat but she does not; The right side of her neck swelled up the size of two baseballs. It would get smaller then get bigger for two days ever since 31AUG2021 and after two days; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (The right side of her neck swelled up the size of two baseballs. It would get smaller then get bigger for two days ever since 31AUG2021 and after two days) and DYSPHAGIA (Still does not feel right, like when she swallows/Touch or swallow feels different like she has a lump in her throat but she does not) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 062E21A) for COVID-19 vaccination.     The patient's past medical history included Aortic dissection in 2012 and Splenectomy.    On 30-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Aug-2021, the patient experienced SWELLING (The right side of her neck swelled up the size of two baseballs. It would get smaller then get bigger for two days ever since 31AUG2021 and after two days). On an unknown date, the patient experienced DYSPHAGIA (Still does not feel right, like when she swallows/Touch or swallow feels different like she has a lump in her throat but she does not). The patient was treated with IBUPROFEN for Neck swelling, at an unspecified dose and frequency. At the time of the report, SWELLING (The right side of her neck swelled up the size of two baseballs. It would get smaller then get bigger for two days ever since 31AUG2021 and after two days) was resolving and DYSPHAGIA (Still does not feel right, like when she swallows/Touch or swallow feels different like she has a lump in her throat but she does not) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  On 31-Aug-2021, The right side of neck swelled up the size of two baseballs. It would get smaller then get bigger for two days ever since 31-Aug-2021 and after two days, the swelling went down, and it stopped doing that. Since then the right side of her neck has not been the same. it looks good, but it still did not feel right, like when she swallows. She could touch the left side it feels fine, but the right side does not feel fine. She did not think she would be getting her second vaccine due to the swelling of her neck. Touch or swallow felts different like she has a lump in her throat but she did not.
This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On an unknown date, the patient might have received an improperly stored dose of PNEUMOVAX 23 (exact dose, route of administration, lot # and expiration date were not reported). The administered dose underwent a temperature excursion of -1 degrees Celsius for 24 hours. There were no previous excursion reported and a digital data logger was not involved. No adverse effect was reported. No product quality complaint was involved. Additional information has been requested.
Information has been received from a registered nurse; concerning a friend of hers who developed shingles 3 days after her children received a booster for VARIVAX (Merck). The patient had not recovered. No further information is available.
Ringing in Ears, doesn't go away, can only be drowned out, Still affects me now(12/3/2022) but either a bit less or I've tuned it out somewhat.
I began to have chest pains two days after the injection.  The pain grew increasingly frequent and sharp.; This is a spontaneous report from a contactable Health Care Professional. This is a report received from a sponsored program. A 67 year old female patient received the 1st dose of BNT162B2 (PFIZER BIONTECH mRNA COVID-19 VACCINE; Batch Number: EN6200) on the Left Arm on 19Feb2021 at 13.00 for COVID-19 immunisation by a Doctor. Medical history of the patient included high BP, depression, fatty liver, obesity. Past drug history of the patient included allergies to ibuprophen and diovan. Concomitant medications included atenolol, (MANUFACTURER UNKNOWN), cymbalta, norvasc, hydrodiuril, entocort. The patient was not enrolled in any clinical trial. The patient did not undergo COVID-19 virus test prior to the vaccination. The patient has not been tested positive for COVID -19 since taking the vaccine. On 21Feb2021 i.e. two days after the injection the patient experienced chest pain. The pain grew increasingly frequent and sharp. She described the pain as although it was a familiar pain that she had most of her life whenever her body was under any physical stress, this was the very worst it's ever been. The reaction outcome of the event was recovering. No follow-up attempts are possible. No further information is expected.
Pt. was administered the MENACTRA vaccine on: left deltoid. A minute after administration pt. fainted. In less than two minutes, pt. regained consciousness and stated that he felt dizzy, all vitals were stable.